Search Results for "f"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for f. Results 681 to 690 of 864 total matches.

Drugs in the Elderly

   
The Medical Letter on Drugs and Therapeutics • Jan 16, 2006  (Issue 1226)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
The physiologic changes that occur with aging can affect the pharmacokinetics and pharmacodynamics of many prescription and over-the-counter drugs, increasing the likelihood of adverse effects.
Med Lett Drugs Ther. 2006 Jan 16;48(1226):6-7 |  Show IntroductionHide Introduction

Phosphate Binders

   
The Medical Letter on Drugs and Therapeutics • Feb 13, 2006  (Issue 1228)
., Vanderbilt School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D ...
Hyperphosphatemia in end-stage renal disease can lead to secondary hyperparathyroidism, renal osteodystrophy, metastatic calcification and cardiovascular mortality. addition to dietary restriction of phosphorus and hemodialysis, drugs that bind phosphates in the gut are usually needed as well. Aluminum hydroxide is no longer recommended for long-term use because of concerns about its toxicity.
Med Lett Drugs Ther. 2006 Feb 13;48(1228):15-6 |  Show IntroductionHide Introduction

Rituximab (Rituxan) for Rheumatoid Arthritis

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006  (Issue 1233)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
Rituximab (Rituxan - Genentech), an anti-CD20 monoclonal antibody already marketed for treatment of B-cell non-Hodgkin's lymphoma, is now FDA-approved for use concurrently with methotrexate to treat moderate to severe rheumatoid arthritis in patients who have had an inadequate response to one or more tumor necrosis factor (TNF) inhibitors. Rituximab selectively depletes CD20+ B cells, which apparently play a role in the autoimmune response and in the chronic synovitis associated with rheumatoid arthritis.
Med Lett Drugs Ther. 2006 Apr 24;48(1233):34-5 |  Show IntroductionHide Introduction

Ranolazine (Ranexa) for Chronic Angina

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 2006  (Issue 1236)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The FDA has approved the marketing of extended release (ER) ranolazine (Ranexa - CV Therapeutics) for treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs. It should be used in combination with a nitrate, a beta-blocker or the dihydropyridine calcium-channel blocker amlodipine (Norvasc), and appears to be more effective in men. The labeling for ranolazine specifies amlodipine as the calcium-channel blocker of choice because the use of other dihydropyridines with ranolazine has not been studied, and use with diltiazem (Cardizem, and...
Med Lett Drugs Ther. 2006 Jun 5;48(1236):46-7 |  Show IntroductionHide Introduction

A Betamethasone-Calcipotriene Combination for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Jul 03, 2006  (Issue 1238)
, M.D., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt School of Medicine F. Estelle ...
Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis vulgaris in patients ≥ 18 years old.
Med Lett Drugs Ther. 2006 Jul 3;48(1238):55-6 |  Show IntroductionHide Introduction

VariZIG for Prophylaxis After Exposure to Varicella

   
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006  (Issue 1241)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
The US manufacturer of varicella zoster immune globulin (VZIG; Massachusetts Public Health Biologic Laboratories, Boston, MA) recently discontinued its production. A Canadian formulation, VariZIG (Varicella Zoster Immune Globulin [Human] - Cangene Corporation, Winnipeg) is now available in the US under an investigational new drug application expanded access protocol.
Med Lett Drugs Ther. 2006 Aug 14;48(1241):69-70 |  Show IntroductionHide Introduction

A Progestin Implant (Implanon) for Long-Term Contraception

   
The Medical Letter on Drugs and Therapeutics • Oct 09, 2006  (Issue 1245)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
Implanon (Organon), an implantable contraceptive containing the progestin etonogestrel, has been approved by the FDA. Two other implantable contraceptives, Norplant and Jadelle, which both contain levonorgestrel, are FDA-approved but not marketed in the US.
Med Lett Drugs Ther. 2006 Oct 9;48(1245):83-4 |  Show IntroductionHide Introduction

Decitabine (Dacogen) for Myelodysplastic Syndromes

   
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006  (Issue 1247)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
Decitabine (Dacogen - MGI Pharma), a pyrimidine nucleoside analog of cytidine, was approved by the FDA as an orphan drug for treatment of myelodysplastic syndromes (MDS), a heterogeneous group of clonal hemopathies that decrease production of normal blood elements (red cells, white cells and platelets) and are associated with a risk of progression to acute leukemia.
Med Lett Drugs Ther. 2006 Nov 6;48(1247):91-2 |  Show IntroductionHide Introduction

Extended-Release Minocycline (Solodyn) for Acne

   
The Medical Letter on Drugs and Therapeutics • Nov 20, 2006  (Issue 1248)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
The FDA has approved an extended-release formulation of minocycline (Solodyn - Medicis) for once-daily treatment of non-nodular moderate to severe acne.
Med Lett Drugs Ther. 2006 Nov 20;48(1248):95-6 |  Show IntroductionHide Introduction

Two Amlodipine/ARB Combinations for Hypertension

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007  (Issue 1276)
., Vanderbilt University School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H ...
The FDA has approved Exforge (Novartis) and Azor (Daiichi Sankyo), the first combinations of a calcium channel blocker (CCB) with an angiotensin receptor blocker (ARB) for treatment of hypertension. Amlodipine is the CCB in both products. The ARBs are valsartan in Exforge and olmesartan in Azor. All 3 of these drugs are available in fixed-dose combinations with other antihypertensive drugs.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):101-2 |  Show IntroductionHide Introduction